Inverness Medical enters Into Distribution Agreement with Epocal Inc.

Inverness Medical Innovations, Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has entered into a distribution agreement with Epocal Inc. of Ottawa, Canada to distribute its epoc® Blood Analysis System for blood gas and electrolyte testing.  The epoc (enterprise point of care) platform is a point-of-care analysis system which provides wireless bedside blood gas and electrolyte measurement testing solutions.  Utilizing easy to use, low-cost disposable Smart- Cards™, the epoc System produces laboratory quality results in critical and acute care settings in about 30 seconds.  The epoc system received FDA 510(k) clearance in 2006 for marketing in the US and anticipates receiving CE marking in 2010.

Under the five year agreement, Inverness will utilize its strong global sales force to promote the use of this point-of-care system co-exclusively with Epocal in all geographies worldwide, except for Japan, India, Bangladesh, Nepal, Bhutan and Sri Lanka. Inverness paid $20.0 million to Epocal in connection with the entry into the distribution agreement, which provides that Epocal will supply to Inverness, at no charge, all of Inverness’ requirements for Epocal products and Inverness will pay to Epocal 50% of its revenues from the sale of Epocal products.

Imants Lauks, PhD, President and Founder of Epocal, Inc. said : The strategic partnership with Inverness, the world’s leading provider of point-of-care testing, represents a significant milestone achievement for our company.  This collaborative agreement expands the distribution and accelerates the market uptake of the best in class epoc System on a global scale.